Analyst Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Faron Pharmaceuticals Oy (FARN – Research Report) and keeping the price target at £10.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Patrick Trucchio has given his Buy rating due to a combination of factors including the promising results from Faron Pharmaceuticals’ Phase 2 trial of bexmarilimab. The trial demonstrated sustained efficacy in patients with myelodysplastic syndrome (MDS), a group with limited treatment options, which supports the drug’s advancement to a Phase 3 trial. The combination of bexmarilimab with azacitidine showed a strong overall response rate and was well tolerated among patients, indicating its potential as a viable treatment option.
Additionally, Trucchio’s valuation of Faron Pharmaceuticals considers the company’s strategic plans for further data presentations and regulatory engagements, which could enhance the therapeutic potential of bexmarilimab. The financial projections, based on a discounted cash flow and sum-of-the-parts methodology, suggest a significant firm value, justifying the £10 price target. However, the rating also acknowledges risks such as clinical development challenges, competition, and market dynamics, which are factored into the analysis.